BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 26541480)

  • 1. Modular Assembly of Allosteric MEK Inhibitor Structural Elements Unravels Potency and Feedback-Modulation Handles.
    Hartung IV; Pühler F; Neuhaus R; Scholz A; Siemeister G; Geisler J; Hillig RC; von Ahsen O; Hitchcock M
    ChemMedChem; 2015 Dec; 10(12):2004-13. PubMed ID: 26541480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
    Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
    Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
    Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
    Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties.
    Hartung IV; Hammer S; Hitchcock M; Neuhaus R; Scholz A; Siemeister G; Bohlmann R; Hillig RC; Pühler F
    Bioorg Med Chem Lett; 2016 Jan; 26(1):186-93. PubMed ID: 26611920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.
    Hartung IV; Hitchcock M; Pühler F; Neuhaus R; Scholz A; Hammer S; Petersen K; Siemeister G; Brittain D; Hillig RC
    Bioorg Med Chem Lett; 2013 Apr; 23(8):2384-90. PubMed ID: 23474388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.
    Yoshida T; Kakegawa J; Yamaguchi T; Hantani Y; Okajima N; Sakai T; Watanabe Y; Nakamura M
    Oncotarget; 2012 Dec; 3(12):1533-45. PubMed ID: 23237773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901.
    Torti VR; Wojciechowicz D; Hu W; John-Baptiste A; Evering W; Troche G; Marroquin LD; Smeal T; Yamazaki S; Palmer CL; Burns-Naas LA; Bagrodia S
    Mol Cancer Ther; 2012 Oct; 11(10):2274-83. PubMed ID: 22752429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
    Pulici M; Traquandi G; Marchionni C; Modugno M; Lupi R; Amboldi N; Casale E; Colombo N; Corti L; Fasolini M; Gasparri F; Pastori W; Scolaro A; Donati D; Felder E; Galvani A; Isacchi A; Pesenti E; Ciomei M
    ChemMedChem; 2015 Feb; 10(2):276-95. PubMed ID: 25430902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).
    Van Dort ME; Hong H; Wang H; Nino CA; Lombardi RL; Blanks AE; Galbán S; Ross BD
    J Med Chem; 2016 Mar; 59(6):2512-22. PubMed ID: 26943489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumors.
    Kiga M; Nakayama A; Shikata Y; Sasazawa Y; Murakami R; Nakanishi T; Tashiro E; Imoto M
    Sci Rep; 2015 Feb; 5():8155. PubMed ID: 25640451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of EBI-1051: A novel and orally efficacious MEK inhibitor with benzofuran scaffold.
    Lu B; Huang S; Cao J; Hu Q; Shen R; Wan H; Wang D; Yuan J; Zhang L; Zhang J; Zhang M; Tao W; Zhang L
    Bioorg Med Chem; 2018 Feb; 26(3):581-589. PubMed ID: 29317148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
    Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.
    Kim DJ; Lee MH; Reddy K; Li Y; Lim DY; Xie H; Lee SY; Yeom YI; Bode AM; Dong Z
    Carcinogenesis; 2013 May; 34(5):1134-43. PubMed ID: 23354306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric modulators of MEK1: drug design and discovery.
    Shang J; Lu S; Jiang Y; Zhang J
    Chem Biol Drug Des; 2016 Oct; 88(4):485-97. PubMed ID: 27115708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.
    Yuan X; Tang Z; Du R; Yao Z; Cheung SH; Zhang X; Wei J; Zhao Y; Du Y; Liu Y; Hu X; Gong W; Liu Y; Gao Y; Huang Z; Cao Z; Wei M; Zhou C; Wang L; Rosen N; Smith PD; Luo L
    Mol Oncol; 2020 Aug; 14(8):1833-1849. PubMed ID: 32336014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway.
    Adler V; Qu Y; Smith SJ; Izotova L; Pestka S; Kung HF; Lin M; Friedman FK; Chie L; Chung D; Boutjdir M; Pincus MR
    Biochemistry; 2005 Aug; 44(32):10784-95. PubMed ID: 16086581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
    Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
    Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancer.
    Kwon OS; Hong SK; Kwon SJ; Go YH; Oh E; Cha HJ
    Cancer Lett; 2017 Sep; 403():48-58. PubMed ID: 28606806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant HRAS as novel target for MEK and mTOR inhibitors.
    Kiessling MK; Curioni-Fontecedro A; Samaras P; Atrott K; Cosin-Roger J; Lang S; Scharl M; Rogler G
    Oncotarget; 2015 Dec; 6(39):42183-96. PubMed ID: 26544513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.